CMS advises Ypsomed on the sale of DiaExpert to Mediq

Frankfurt/Main – Ypsomed, a leading developer and manufacturer of injection and infusion systems for self-medication as well as a proven diabetes specialist, headquartered in Burgdorf (Switzerland), and Mediq, an international healthcare company, headquartered in Utrecht (Netherlands), have signed an agreement on the sale of DiaExpert. DiaExpert is an established diabetes specialist and mail-order retailer specialised in insulin pump therapy. In the future, Ypsomed intends to focus more on the development, manufacture and sale of its own high-quality medical technology products for people with chronic conditions. The transaction is expected to be completed in the upcoming months and is subject to the usual regulatory approvals.

A CMS team led by Dr Heike Wagner and Dr Tobias Kilian provided comprehensive legal advice to Ypsomed, a Swiss listed medical technology company, on all aspects of the transaction.

CMS Germany

Dr Heike Wagner, Lead Partner, Frankfurt/Main
Dr Tobias Kilian, Of Counsel (Co-Lead), Frankfurt/Main
Reiner Thieme, Associate, Frankfurt/Main, all Corporate/M&A
Dr Roland Wiring, Partner, Hamburg
Jeannine Pettersson, Senior Associate, Hamburg, both Healthcare
Stefan Lehr, Partner, Frankfurt/Main, Competition & EU
Michael Kamps, Partner, Cologne
Dr Karin Schmidtmann, Senior Associate, Cologne, both TMC
Jörg Schrade, Partner, Munich
Eduard Kosavtsev, Associate, Munich, both Tax
Dr Dirk Smielick, Principal Counsel, Cologne, Intellectual Property
Dr Boris Alles, Partner, Frankfurt/Main
Dr Theresa Kipp, Associate, Frankfurt/Main, both Labor, Employment & Pensions

Press Contact
presse@cms-hs.com